| Bioactivity | Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with a Ki of 1.2 μM，Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC50 of 680 nM[1]. | ||||||||||||
| Target | Ki: 1.2 μM (PPARγ LBD); EC: 680 nM (PPARγ LBD) (Leriglitazone) | ||||||||||||
| Name | Leriglitazone | ||||||||||||
| CAS | 146062-44-4 | ||||||||||||
| Formula | C19H20N2O4S | ||||||||||||
| Molar Mass | 372.44 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Mosure SA,et al. Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. J Med Chem. 2019 Feb 28;62(4):2008-2023. |
Leriglitazone
CAS: 146062-44-4 F: C19H20N2O4S W: 372.44
Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.